Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 15/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751368 | 0.92 | FAAH (0.67) | FAAHFFAR1 | |
| SCHEMBL8769199 | 0.89 | FAAH (0.69) | FAAHFFAR1 | |
| SCHEMBL6747894 | 0.86 | FAAH (0.68) | FAAHFFAR1 | |
| SCHEMBL9022793 | 0.84 | FAAH (0.63) | FAAH | |
| SCHEMBL8536279 | 0.83 | FAAH (0.62) | FAAH | |
| SCHEMBL630214 | 0.82 | DRD2 (0.51) | MAPT | |
| SCHEMBL7289390 | 0.82 | DRD2 (0.51) | MAPT | |
| SCHEMBL8536428 | 0.82 | FAAH (0.58) | FAAHFFAR1 | |
| SCHEMBL629707 | 0.81 | FAAH (0.60) | FAAH | |
| SCHEMBL18983644 | 0.81 | FAAH (0.50) | FAAHFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | FAAH 2966/4885FFAR1 550/4885MAPT 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.